TOP > 外国特許検索 > DNA fragment and use thereof

DNA fragment and use thereof

外国特許コード F120006094
整理番号 S2008-0302
掲載日 2012年1月6日
出願国 アメリカ合衆国
出願番号 86599609
公報番号 20110023155
公報番号 8865669
出願日 平成21年2月4日(2009.2.4)
公報発行日 平成23年1月27日(2011.1.27)
公報発行日 平成26年10月21日(2014.10.21)
国際出願番号 JP2009051907
国際公開番号 WO2009099112
国際出願日 平成21年2月4日(2009.2.4)
国際公開日 平成21年8月13日(2009.8.13)
優先権データ
  • 特願2008-024071 (2008.2.4) JP
  • 2009JP051907 (2009.2.4) WO
発明の名称 (英語) DNA fragment and use thereof
発明の概要(英語) The invention relates to a DNA consisting of the nucleotide sequence shown in SEQ ID NO: 1, or a nucleotide sequence the same or substantially the same as a partial nucleotide sequence thereof containing at least one HRE consensus sequence, which transiently has a transcription promoting activity in a vascular endothelial cell-specific manner in a hypoxic state, or a vector containing a promoter containing the DNA, and the like.
The prophylaxis and/or treatment, as well as diagnosis, of acute ischemic diseases are enabled by connecting a prophylactic and/or therapeutic gene or a reporter gene to the downstream of the vector and administering same to mammals.
特許請求の範囲(英語) [claim1]
1. A method for promoting vascular endothelial cell-specific transcription of a gene in cells in an acute ischemic stage in a patient, which comprises administrating to the patient by catheter or injection an expression vector comprising a gene operably linked to a promoter such that an effective amount of the expression vector is delivered to the cells in an acute ischemic stage, wherein the promoter comprises a nucleotide sequence having a sequence identity of not less than 80% to (a) the nucleotide sequence of SEQ ID NO: 1 or (b) the nucleotide sequence of a non-human mammalian ortholog of the nucleotide sequence of SEQ ID NO: 1, wherein the non-human mammalian ortholog is a mouse or rat ortholog, and wherein the gene operably linked to the promoter is transiently expressed in the cells in an acute ischemic stage in the patient in a vascular endothelial cell-specific manner, thereby promoting vascular endothelial cell-specific transcription of the gene in the cells in an acute ischemic stage in the patient.
[claim2]
2. The method of claim 1, wherein the promoter comprises a nucleotide sequence having a sequence identity of not less than 90% to (a) the nucleotide sequence of SEQ ID NO: 1 or (b) the nucleotide sequence of a non-human mammalian ortholog of the nucleotide sequence of SEQ ID NO: 1, wherein the non-human mammalian ortholog is a mouse or rat ortholog.
[claim3]
3. The method of claim 2, wherein the promoter comprises a nucleotide sequence having a sequence identity of not less than 95% to (a) the nucleotide sequence of SEQ ID NO: 1 or (b) the nucleotide sequence of a non-human mammalian ortholog of the nucleotide sequence of SEQ ID NO: 1, wherein the non-human mammalian ortholog is a mouse or rat ortholog.
[claim4]
4. The method of claim 1, wherein the gene is selected from the group consisting of vascular endothelial growth factor (VEGF), erythropoietin, hepatocyte growth factor (HGF), basic fibroblast growth factor (FGF), endothelial-derived nitric oxide synthase (eNOS), integrin-linked kinase, B-cell lymphoma (Bcl)-2, Bcl-xL, Bclw, and myeloid cell leukemia (Mcl)-1.
[claim5]
5. The method of claim 1, wherein the expression vector is administered to the patient by catheter.
[claim6]
6. The method of claim 1, wherein the expression vector is administered to the patient by injection.
[claim7]
7. The method of claim 1, wherein the promoter comprises the nucleotide sequence of SEQ ID NO: 1.
[claim8]
8. The method of claim 7, wherein the expression vector is administered to the patient by catheter.
[claim9]
9. The method of claim 7, wherein the expression vector is administered to the patient by injection.
[claim10]
10. The method of claim 1, wherein the promoter comprises the nucleotide sequence of a non-human mammalian ortholog of the nucleotide sequence of SEQ ID NO: 1, wherein the non-human mammalian ortholog is a mouse or rat ortholog.
[claim11]
11. The method of claim 10, wherein the expression vector is administered to the patient by catheter.
[claim12]
12. The method of claim 10, wherein the expression vector is administered to the patient by injection.
[claim13]
13. A method for promoting vascular endothelial cell-specific transcription of a gene in cells in an acute ischemic stage in a patient, which comprises administering an expression vector comprising a gene operably linked to a promoter directly to the cells in an acute ischemic stage in the patient, wherein the promoter comprises a nucleotide sequence having a sequence identity of not less than 80% to (a) the nucleotide sequence of SEQ ID NO: 1 or (b) the nucleotide sequence of a non-human mammalian ortholog of the nucleotide sequence of SEQ ID NO: 1, wherein the non-human mammalian ortholog is a mouse or rat ortholog, and wherein the gene operably linked to the promoter is transiently expressed in the cells in an acute ischemic stage in the patient in a vascular endothelial cell-specific manner, thereby promoting vascular endothelial cell-specific transcription of the gene in the cells in an acute ischemic stage in the patient.
[claim14]
14. The method of claim 13, wherein the promoter comprises a nucleotide sequence having a sequence identity of not less than 90% to (a) the nucleotide sequence of SEQ ID NO: 1 or (b) the nucleotide sequence of a non-human mammalian ortholog of the nucleotide sequence of SEQ ID NO: 1, wherein the non-human mammalian ortholog is a mouse or rat ortholog.
[claim15]
15. The method of claim 14, wherein the promoter comprises a nucleotide sequence having a sequence identity of not less than 95% to (a) the nucleotide sequence of SEQ ID NO: 1 or (b) the nucleotide sequence of a non-human mammalian ortholog of the nucleotide sequence of SEQ ID NO: 1, wherein the non-human mammalian ortholog is a mouse or rat ortholog.
[claim16]
16. The method of claim 13, wherein the promoter comprises the nucleotide sequence of SEQ ID NO: 1.
[claim17]
17. The method of claim 13, wherein the promoter comprises the nucleotide sequence of a non-human mammalian ortholog of the nucleotide sequence of SEQ ID NO: 1, wherein the non-human mammalian ortholog is a mouse or rat ortholog.
  • 発明者/出願人(英語)
  • HIROHATA SATOSHI
  • NINOMIYA YOSHIFUMI
  • KUSACHI SHOZO
  • OMER FARUK HATIPOGLU
  • OKAYAMA UNIVERSITY
国際特許分類(IPC)
米国特許分類/主・副
  • 514/44.000R
  • 435/320.1
  • 536/23.1
  • 536/24.1

PAGE TOP

close
close
close
close
close
close